Thrombotic phenotype of mice with a combined deficiency in plasminogen activator inhibitor 1 and vitronectin

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 10, 2005, Pages 2290-2295

  Koschnick, S ^a,b   Konstantinides, S ^b   Schafer K ^b   Crain, K ^a   Loskutoff, David J ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Embolization; Knockout mice; Plasminogen activator inhibitor 1; Thrombosis; Vitronectin

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; VITRONECTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY BLOOD FLOW; ARTICLE; BLOOD VESSEL OCCLUSION; CAROTID ARTERY; CONTROLLED STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; THROMBOGENESIS; THROMBOSIS; VASCULAR PATENCY; WILD TYPE;

ANIMALS; FERRIC COMPOUNDS; MICE; MICE, KNOCKOUT; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOSIS; TIME FACTORS; VASCULAR PATENCY; VITRONECTIN;

EID: 28444446680     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01479.x     Document Type: Article

References (28)

1. Stefansson S, McMahon GA, Petitclerc C, Lawrence DA. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des 2003; 9: 1545-64.
2. Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005; 93: 631-40.
3. Erickson LA, Hekman CM, Loskutoff DJ. The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. Proc Natl Acad Sci USA 1985; 82: 8710-4.
4. Fay WP, Eitzman DT, Shapiro AD, Madison EL, Ginsburg D. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and-independent mechanisms. Blood 1994; 83: 351-6.
5. Lambers JWJ, Cammenga M, Konig B, Pannekoek H, van Mourik JA. Activation of human endothelial cell-type plasminogen activator inhibitor (PAI-1) by negatively charged phospholipids. J Biol Chem 1987; 262: 17492-6.
6. Stringer HAR, van Swieten P, Heijnen HFG, Sixma JJ, Pannekoek H. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance: studies with thrombi generated in the chandler loop. Arterioscler Thromb 1994; 14: 1452-8.
7. Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999; 99: 3050-5.
8. Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
9. Seiffert D, Keeton M, Eguchi Y, Sawdey M, Loskutoff DJ. Detection of vitronectin mRNA in tissues and cells of the mouse. Proc Natl Acad Sci USA 1991; 88: 9402-6.
10. Preissner KT, Seiffert D. Role of vitronectin and its receptor in haemostasis and vascular remodeling. Thromb Res 1998; 89: 1-21.
11. Preissner KT, Holzhuter S, Justus C, Muller-Berghaus G. Identification and partial characterization of platelet vitronectin: evidence for complex formation with platelet-derived plasminogen activator inhibitor-1. Blood 1989; 74: 1989-96.
12. Seiffert D, Schleef RR. Two functionally distinct pools of vitronectin (Vn) in the blood circulation: identification of a heparin-binding competent population of Vn within platelet α-granules. Blood 1996; 88: 552-60.
13. Declerck PJ, De Mol M, Alessi M-C, Baudner S, Paques E-P, Preissner K, Muller-Berghaus G, Collen D. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988; 263: 15454-61.
14. Seiffert D, Ciambrone G, Wagner NV, Binder BB, Loskutoff DJ. The somatomedin B domain of vitronectin: structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J Biol Chem 1994; 269: 2659-66.
15. Ehrlich HJ, Gebbink RK, Keijer J, Linders M, Preissner KT, Pannekoek H. Alteration of serpin specificity by a protein cofactor: vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem 1990; 265: 13029-35.
16. Asch E, Podack E. Vitronectin binds to activated human platelets and plays a role in platelet aggregation. J Clin Invest 1990; 85: 1372-8.
17. Tomasini BR, Mosher DF. Vitronectin. In: Coller BS, ed. Progress in Hemostasis and Thrombosis. Philadelphia, USA: W.B. Saunders, 1990: 269-305.
18. Carmeliet P, Kieckens L, Schoonjans L, Ream B, Van Nuffelen A, Prendergast G, Cole M, Bronson R, Collen D, Mulligan RC. Plasminogen activator inhibitor-1 gene-deficient mice: I. Generation by homologous recombination and characterization. J Clin Invest 1993; 92: 2746-55.
19. Zheng X, Saunders TL, Camper SA, Samuelson LC, Ginsburg D. Vitronectin is not essential for normal mammalian development and fertility. Proc Natl Acad Sci U S A 1995; 92: 12426-30.
20. Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990; 60: 269-80.
21. Konstantinides S, Schäfer K, Thinnes T, Loskutoff DJ. Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi following vascular injury in mice. Circulation 2001; 103: 576-83.
22. Farrehi PM, Ozaki CK, Carmeliet P, Fay WP. Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation 1998; 97: 1002-8.
23. Carmeliet P, Stassen JM, Schoonjans L, Ream B, Van den Oord JJ, De Mol M, Mulligan RC, Collen D. Plasminogen activator inhibitor-1 gene-deficient mice: II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 1993; 92: 2756-60.
24. Konstantinides S, Schäfer K, Loskutoff DJ. Do PAI-1 and vitronectin promote or inhibit neointima formation? The exact role of the fibrinolytic system in vascular remodeling remains uncertain. Arterioscler Thromb Vasc Biol 2002; 22: 1943-5.
25. Podor TJ, Peterson CB, Lawrence DA, Stefansson S, Shaughnessy SG, Foulon DM, Butcher M, Weitz JI. Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin. J Biol Chem 2000; 275: 19788-94.
26. Podor TJ, Singh D, Chindemi P, Foulon DM, McKelvie R, Weitz JI, Austin R, Boudreau G, Davies R. Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface. J Biol Chem 2002; 277: 7529-39.
27. Chico TJ, Chamberlain J, Gunn J, Arnold N, Bullens SL, Gadek TR, Francis SE, Bunting S, Horton M, Shepherd L, Lipari MT, Quan C, Knolle J, Stilz HU, Peyman A, Crossman DC. Effect of selective or combined inhibition of integrins alpha(IIb)beta(3) and alpha(v)beta(3) on thrombosis and neointima after oversized porcine coronary angioplasty. Circulation 2001; 103: 1135-41.
28. Wu YP, Bloemendal HJ, Voest EE, Logtenberg T, de Groot PG, Gebbink MF, de Boer HC. Fibrin-associated vitronectin is involved in platelet adhesion and thrombus formation through homotypic interactions with platelet-associated vitronectin. Blood 2004.